TTX 114
Alternative Names: TTX-114Latest Information Update: 15 Jan 2024
At a glance
- Originator Trueline Therapeutics
- Class Antineoplastics
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Proto-oncogene protein c-hck inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 11 Oct 2023 Pharmacodynamics data from preclinical studies in Haematological malignancies presented at the International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2023)
- 24 May 2023 TTX 114 is available for licensing as of 24 May 2023. https://truelinetx.com/#home (Trueline Therapeutics pipeline, May 2023)
- 24 May 2023 Preclinical trials in Haematological malignancies in Germany (PO) (Trueline Therapeutics pipeline, May 2023)